Morgan Stanley Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock

Henry Schein (NASDAQ:HSIC) had its price objective raised by analysts at Morgan Stanley from $58.00 to $61.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “underweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential downside of 25.13% from the stock’s current price.

HSIC has been the subject of several other research reports. Wells Fargo & Company raised their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Evercore increased their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Leerink Partners boosted their target price on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday. Finally, Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $85.58.

Henry Schein Trading Down 0.5%

Shares of HSIC stock opened at $81.47 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38. The firm has a fifty day moving average of $77.75 and a 200-day moving average of $72.04. Henry Schein has a 52-week low of $60.56 and a 52-week high of $89.29. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 2.43 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities research analysts forecast that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC bought a new position in Henry Schein in the 4th quarter worth approximately $30,000. Federated Hermes Inc. acquired a new position in Henry Schein during the 4th quarter worth $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.